Chris Raymond
Stock Analyst at Raymond James
(2.92)
# 1,382
Out of 5,182 analysts
9
Total ratings
66.67%
Success rate
49.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNPR Monopar Therapeutics | Downgrades: Outperform | $142 → $123 | $52.15 | +135.86% | 3 | Nov 14, 2025 | |
| SION Sionna Therapeutics | Initiates: Strong Buy | $45 | $38.70 | +16.28% | 1 | Sep 3, 2025 | |
| TYRA Tyra Biosciences | Initiates: Strong Buy | $35 | $34.75 | +0.72% | 1 | Sep 3, 2025 | |
| NUVL Nuvalent | Initiates: Outperform | $105 | $100.28 | +4.71% | 1 | Sep 3, 2025 | |
| KLRS Kalaris Therapeutics | Initiates: Strong Buy | $23 | $5.52 | +316.67% | 1 | Sep 3, 2025 | |
| COGT Cogent Biosciences | Initiates: Strong Buy | $30 | $35.79 | -16.18% | 1 | Sep 3, 2025 | |
| BHVN Biohaven | Initiates: Strong Buy | $75 | $9.59 | +682.06% | 1 | Sep 3, 2025 |
Monopar Therapeutics
Nov 14, 2025
Downgrades: Outperform
Price Target: $142 → $123
Current: $52.15
Upside: +135.86%
Sionna Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $45
Current: $38.70
Upside: +16.28%
Tyra Biosciences
Sep 3, 2025
Initiates: Strong Buy
Price Target: $35
Current: $34.75
Upside: +0.72%
Nuvalent
Sep 3, 2025
Initiates: Outperform
Price Target: $105
Current: $100.28
Upside: +4.71%
Kalaris Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $23
Current: $5.52
Upside: +316.67%
Cogent Biosciences
Sep 3, 2025
Initiates: Strong Buy
Price Target: $30
Current: $35.79
Upside: -16.18%
Biohaven
Sep 3, 2025
Initiates: Strong Buy
Price Target: $75
Current: $9.59
Upside: +682.06%